Skip to content

About Us
Pipeline
For Patients
Publications
Investors
Careers
Contact

About Us
Pipeline
For Patients
Publications
Investors
Careers
Contact

TALETRECTINIB

Updated Efficacy and Safety of Taletrectinib in Patients with ROS1+ Non–Small Cell Lung Cancer (pdf)

Publications, TALETRECTINIB / natalia

Updated Efficacy and Safety of Taletrectinib in Patients with ROS1+ Non–Small Cell Lung Cancer (pdf) Read More »

TRUST-II: a Global Phase II Study of Taletrectinib in ROS1-Positive Non-Small-Cell Lung Cancer and Other Solid Tumors

Publications, TALETRECTINIB / natalia

PMID: 36877099

TRUST-II: a Global Phase II Study of Taletrectinib in ROS1-Positive Non-Small-Cell Lung Cancer and Other Solid Tumors Read More »

TRUST: The Efficacy and Safety of Taletrectinib in TKI-Naïve or Crizotinib-Pretreated ROS1-Positive Non-Small Cell Lung Cancer (NSCLC) Patients (pdf)

Publications, TALETRECTINIB / natalia

TRUST: The Efficacy and Safety of Taletrectinib in TKI-Naïve or Crizotinib-Pretreated ROS1-Positive Non-Small Cell Lung Cancer (NSCLC) Patients (pdf) Read More »

A Global Phase 2 Study of Taletrectinib, a Next Generation of ROS1 TKI, in ROS1 Positive Lung Cancer and Other Solid Tumors (TRUST II) (pdf)

Publications, TALETRECTINIB / natalia

A Global Phase 2 Study of Taletrectinib, a Next Generation of ROS1 TKI, in ROS1 Positive Lung Cancer and Other Solid Tumors (TRUST II) (pdf) Read More »

A Phase II Clinical Study to Investigate Taletrectinib (AB-106) in Treating Patients with ROS1 Fusion Positive Non-Small Cell Lung Cancer (TRUST Phase II study) (pdf)

Publications, TALETRECTINIB / natalia

A Phase II Clinical Study to Investigate Taletrectinib (AB-106) in Treating Patients with ROS1 Fusion Positive Non-Small Cell Lung Cancer (TRUST Phase II study) (pdf) Read More »

Preliminary Results from TRUST: A Phase II Clinical Study to Investigate Taletrectinib in Treating Patients with ROS1 Fusion Positive Non-small Cell Lung Cancer (NSCLC) (pdf)

Publications, TALETRECTINIB / natalia

Preliminary Results from TRUST: A Phase II Clinical Study to Investigate Taletrectinib in Treating Patients with ROS1 Fusion Positive Non-small Cell Lung Cancer (NSCLC) (pdf) Read More »

Efficacy of Taletrectinib (AB-106/DS-6051b) in ROS1+ NSCLC: An Updated Pooled Analysis of U.S. and Japan Phase 1 Studies

Publications, TALETRECTINIB / natalia

PMID: 34589973 PMCID: PMC8474193 DOI: 10.1016/j.jtocrr.2020.100108

Efficacy of Taletrectinib (AB-106/DS-6051b) in ROS1+ NSCLC: An Updated Pooled Analysis of U.S. and Japan Phase 1 Studies Read More »

U.S. Phase I First-in-human Study of Taletrectinib (DS-6051b/AB-106), a ROS1/TRK Inhibitor, in Patients with Advanced Solid Tumors

Publications, TALETRECTINIB / natalia

PMID: 32591465 DOI: 10.1158/1078-0432.CCR-20-1630

U.S. Phase I First-in-human Study of Taletrectinib (DS-6051b/AB-106), a ROS1/TRK Inhibitor, in Patients with Advanced Solid Tumors Read More »

The New-Generation Selective ROS1/NTRK Inhibitor DS-6051b Overcomes Crizotinib Resistant ROS1-G2032R Mutation in Preclinical Models

Publications, TALETRECTINIB / natalia

PMID: 31399568 PMCID: PMC6688997 DOI: 10.1038/s41467-019-11496-z

The New-Generation Selective ROS1/NTRK Inhibitor DS-6051b Overcomes Crizotinib Resistant ROS1-G2032R Mutation in Preclinical Models Read More »

Safety and Pharmacokinetics of DS-6051b in Japanese Patients with Non-small Cell Lung Cancer Harboring ROS1 Fusions: a Phase I Study

Publications, TALETRECTINIB / natalia

PMID: 29805770 PMCID: PMC5955103 DOI: 10.18632/oncotarget.25263

Safety and Pharmacokinetics of DS-6051b in Japanese Patients with Non-small Cell Lung Cancer Harboring ROS1 Fusions: a Phase I Study Read More »

Post pagination

← Previous 1 2

Nuvation Bio is a global biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel product candidates.

About us

Management Team
Board of Directors
Scientific Advisory Board
Pipeline
News
Careers
Contact

Management Team
Board of Directors
Scientific Advisory Board
Pipeline
News
Careers
Contact

General Inquiries

info@nuvationbio.com

Media or Investor Inquiries

IR@nuvationbio.com

© 2024 NUVATION BIO INC. ALL RIGHTS RESERVED. TERMS AND CONDITIONS | PRIVACY

Manage Consent

To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.

Functional Functional Always active

The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.

Preferences Preferences

The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.

Statistics Statistics

The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.

Marketing Marketing

The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.

Manage options Manage services Manage {vendor_count} vendors Read more about these purposes

View preferences

{title} {title} {title}

Manage Consent

To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.

Functional Functional Always active

The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.

Preferences Preferences

The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.

Statistics Statistics

The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.

Marketing Marketing

The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.

Manage options Manage services Manage {vendor_count} vendors Read more about these purposes

View preferences

{title} {title} {title}